A Focus of Dogs and *Rickettsia massiliae*–Infected *Rhipicephalus sanguineus* in California

Emily Beeler, Kyle F. Abramowicz, Maria L. Zambrano, Michele M. Sturgeon, Nada Khalaf, Renjie Hu, Gregory A. Dasch, and Marina E. Eremeeva*

*Rickettsial Zoonoses Branch, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Veterinary Public Health and Rabies Control Program, Los Angeles County Department of Public Health, Los Angeles, California; VCA McClave Animal Hospital, Reseda, California; Vector-Borne Disease Section, Center for Infectious Diseases, California Department of Public Health, Ontario, California*

**Abstract.** A recurrent focus of *Rhipicephalus sanguineus* infestation was investigated in a suburban area of southern California after reports of suspected Rocky Mountain spotted fever in two dogs on the same property. Abundant quantities of *Rh. sanguineus* were collected on the property and repeatedly from each dog, and *Rickettsia massiliae* DNA was detected by polymerase chain reaction (PCR). Whole blood and serum samples from four dogs were tested by using PCR and microimmunofluorescent assay for antibodies against spotted fever group rickettsiae. Serum samples from all four dogs contained antibodies reactive with *R. massiliae*, *R. rickettsi*, and 364D *Rickettsia* but no rickettsial DNA was detected by PCR of blood samples. Serum cross-absorption and Western blot assays implicated *R. massiliae* as the most likely spotted fever group rickettsiae responsible for seropositivity. To our knowledge, this is the first detection of *R. massiliae* in ticks in California.

**INTRODUCTION**

*Rickettsia massiliae* Mtul was first isolated in 1990 from a *Rhipicephalus turanicus* tick collected from a horse in Le Sambuc, Bouches-du Rhone, France. Its formal taxonomic species description appeared in 1993. Other isolates of *R. massiliae* were later obtained from *Rhipicephalus sanguineus* from Spain (Bar29), France (Mtus5), Greece (GS), and Arizona (AZT80), USA. Different genotypes of *R. massiliae* have been detected in several other ticks of the so-called *Rhipicephalus* spp. complex including Mtus5 genotype in *Rh. senegalensis*, and Mtul genotype in *Rh. sulcatus*, *Rh. lunulatus* and *Rh. mushamae* in central Africa, and Bar29 genotype in *Rh. sanguineus* and *Rh. turanicus* in Switzerland. The distribution of *R. massiliae* and its association with different *Rhipicephalus* spp. was subsequently extended to other Mediterranean and African countries, and to Argentina. The reported prevalence of *R. massiliae* in ticks has varied from 4.7% to 18%. However, the true prevalence and range of distribution of *R. massiliae* in *Rhipicephalus* ticks are unknown, especially in the New World. Whether the specific genetic types of *R. massiliae* have adapted preferentially to different tick vectors, animal hosts, and whether their potential to cause febrile illness varies are unknown.

The first confirmed human case of *R. massiliae* infection was reported in 2006. It was diagnosed by polymerase chain reaction (PCR) and sequence characterization of a 1984 cell culture isolate from a blood sample collected from a man hospitalized in Sicily with fever, maculopapular rash on the palms and soles, mild hepatomegaly, and an eschar. In 2008 in France, a second patient was diagnosed with similar clinical symptoms that included two eschars on the thigh and buttock, and bilateral choriorretinitis with acute blindness. The latest case was diagnosed in Spain by retrospective PCR testing of eschar tissue from a female patient from Buenos Aires, Argentina.

There may have been additional cases of human infection with *R. massiliae*. Children diagnosed with Mediterranean spotted fever in Catalonia, an area that is endemic for the Bar29 isolate of *R. massiliae*, were refractory to treatment with rifampin, tested as an alternative antibiotic when tetracycline was contraindicated. *R. massiliae* is resistant to rifampin *in vitro*, and *R. conorii* (the etiologic agent of Mediterranean spotted fever) is not resistant.

The similar clinical manifestations, common vector within the area endemic for Mediterranean spotted fever, and primary use of cross-reactive serologic assays for diagnosis of rickettsial diseases complicate understanding the true prevalence and distribution of *R. massiliae* and associated human or potentially canine infections. A limited canine sera survey in northeastern Spain demonstrated that 8.6–25% (n = 93) of Catalanian dogs were exposed to *R. massiliae* Bar29 and 4–20% to *R. conorii* or another cross-reacting *Rickettsia*. A survey of *Rh. sanguineus*-infested dogs in Seville Province, Spain, showed that 18% were carrying ticks infected with *R. massiliae*. Because dogs are recognized sentinels for human rickettsial diseases, these findings may correlate with a higher prevalence of human cases caused by *R. massiliae* in areas where this agent is found.

We report the results of an investigation triggered by reports of sick dogs living on a property in Los Angeles County, California, with sustained infection by *Rh. sanguineus*. We found that *R. massiliae* is present in California ticks and show the efficient long-term maintenance of *R. massiliae* in this naturally infected population of *Rh. sanguineus*. We also report serologic evidence for canine exposure to this *Rickettsia*, and demonstrate the lack of obvious negative effect of canine anti-rickettsial antibodies on tick feeding and circulation of *R. massiliae* in those ticks.

**MATERIALS AND METHODS**

**Study description.** In August 2007 and March 2008, the Los Angeles County Veterinary Public Health and Rabies Control Program (LACVPH) was notified about two ill dogs on the same property suspected of having Rocky Mountain spotted fever, a rare condition in the area. Both dogs were seropositive to spotted fever group rickettsiae (SFGR), as established by testing at the commercial laboratory, and had a heavy infestation with the brown dog tick *Rh. sanguineus*. The
LACVPH reviewed the clinical history, treatment outcome, and commercial laboratory testing results of these dogs. Whole blood treated with EDTA and serum were collected from both case dogs and from two housemate apparently healthy dogs and submitted to the Rickettsial Zoonoses Branch, Centers for Disease Control and Prevention (CDC) (Atlanta, GA) for further testing. Ticks were also collected from the property and dogs and submitted to the CDC for testing. The owner was advised on tick control and prevention measures.

**Preparation of antigens for electrophoresis and Western blotting.** *Rickettsia rickettsii* strain Bitterroot, *R. massiliae* strain AZT80, *R. rhipicephali* strains 3-7-6-6 and CA871, and 364D *Rickettsia* were cultivated in African green monkey kidney cells (E6-Vero), harvested, and purified from the host cells using centrifugation through 25–45% (w/v) Renografin (Nycomed, Inc., Princeton, NJ) gradients as described. Purified rickettsiae were kept frozen in aliquots (10 mg of protein/mL) in sterile distilled water at –80°C until used for electrophoresis and Western blotting.

For electrophoresis, suspensions of purified rickettsiae were diluted in water to a concentration of 3 mg of protein/mL, and an equal volume of 2× Laemmli sample solubilizing buffer (125 mM Tris-HCl, pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol, 10% β-mercaptoethanol, 0.001% bromophenol blue dye) was added at room temperature.

**Indirect microimmunofluorescence testing.** Antigens consisted of the *Rickettsia*-infected nuclear fraction collected as a by-product of the rickettsial purification from infected cells; it was resuspended and frozen in SRM buffer (0.281 M sucrose, 5 mM potassium glutamate buffer, pH 7.0, supplemented with 1% Renografin-76 and 5 mM MgCl₂), and gamma irradiated with 1,000,000 Rads. The stock was thawed, the SRM was removed after centrifugation, the pellet was suspended in phosphate-buffered saline, pH 7.2, and 10-μL aliquots of antigens were spotted onto glass slides, air-dried, and fixed in acetone.

Serum samples were screened by indirect immunofluorescent antibody (IFA) assay at consecutive 2-fold serum dilutions starting at 1:32 in a dilution buffer (phosphate-buffered saline, pH 7.4, supplemented with 1% bovine serum albumin and 1% normal goat serum) to the last visible endpoint or a 1:2,048 dilution. For the detection of IgM, IgG was first absorbed with a Mini Rapi-Sep-M kit (Panbio Diagnostics, Columbia, MD) according to the manufacturer’s instructions. Fluorescein isothiocyanate–labeled goat anti-dog IgM (anti-μ chain) and anti-dog IgG (anti-γ chain) (Kirkegaard and Perry Laboratories, Gaithersburg, MD) were diluted 1:100 and 1:150, respectively. IgG and IgM titers ≥ 1:64 were considered positive.

**Protein gel electrophoresis and Western blotting.** Solubilized lysates of rickettsiae (15 μg at a concentration of 1.5 mg/mL) were loaded onto 12.5% sodium dodecyl sulfate–polyacrylamide gels, pH 8.8, with a 3% stacking gel, pH 6.8. Proteins were separated by electrophoresis at 3 mA for 1 hour through the stacking gel and at 12 mA for 2 hours through the separating gel at room temperature in a Mini-Protein Gel chamber (Bio-Rad, Hercules, CA) as described. Absorption antigens were prepared by solubilization of the *Rickettsia*-infected fraction of Vero cells (same stocks as used with IFA testing) using CellLyticTM B II Bacterial Cell Lysis Reagent (Sigma, St. Louis, MO) supplemented with lysozyme and protease inhibitor cocktail according to the manufacturer’s instructions. Protein concentration was measured by using the bicinchoninic acid protein assay (Pierce, Rockford, IL) and normalized to a concentration of 1 mg/mL of the estimated rickettsial protein content. Serum absorptions were performed overnight at room temperature by using the solubilized nuclear fractions. Unabsorbed and absorbed serum specimens were incubated for 1.5 hours with membranes at final dilutions of 1:200–1:10,000 in 2% nonfat dry milk in TTBS buffer. To detect specific antigen–antibody complex formation, peroxidase-conjugated goat anti-dog IgG (heavy plus light chain; Kirkegaard and Perry Laboratories) diluted 1:1,000 in 2% nonfat dry milk in TTBS buffer were incubated with the membrane for 1.5 hours. Bound enzyme was detected by reaction with substrate solution containing 0.015% 4-chloro-1-naphthol (Bio-Rad) and 0.015% hydrogen peroxide.

**Tick collection and processing.** Ticks were collected from the dogs by the primary care veterinarian and by the dog owner from the property and sent to the CDC by LACVPH for further testing (Table 1). Ticks were identified to species by using standard taxonomic keys. Molecular identification of selected ticks was performed by sequencing of a fragment of the 12S mitochondrial ribosomal RNA gene as described.

**PCR testing and sequence analysis.** DNA was extracted from organ tissues of dog A and whole blood samples by using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer’s instructions and stored at 4°C before analysis. Canine DNA samples were tested by nested PCR that amplified the 17-kD protein gene and by SYBR Green PCR specific for an outer membrane protein A (*ompA*) gene fragment.

Four microliters of DNA extracted from individual ticks was tested for SFGR by using the *ompA* SYBR Green PCR assay as described. Genomic DNA of *R. slovaca* and *R. sibirica* were run on every plate as positive controls; four no template controls were included on each plate to ensure

---

**Table 1**

Detection of persistent presence of spotted fever group rickettsiae in *Rhipicephalus sanguineus*, California*

<table>
<thead>
<tr>
<th>Date collected</th>
<th>Source of ticks</th>
<th>No. collected</th>
<th>Total PCR positive</th>
<th>Female (no. positive/no tested)</th>
<th>Male (no. positive/no tested)</th>
<th>No sequenced</th>
<th>Rickettsial prevalence, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/24/2008</td>
<td>Dog B</td>
<td>15</td>
<td>12</td>
<td>9/12</td>
<td>3/3</td>
<td>5</td>
<td>80</td>
</tr>
<tr>
<td>4/3/2008</td>
<td>Property yard</td>
<td>50</td>
<td>32</td>
<td>2/2</td>
<td>30/48</td>
<td>4</td>
<td>64</td>
</tr>
<tr>
<td>4/3/2009</td>
<td>Dog A</td>
<td>23</td>
<td>0</td>
<td>0</td>
<td>0/12</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4/16/2009</td>
<td>Dog A</td>
<td>48</td>
<td>17</td>
<td>9/24</td>
<td>8/24</td>
<td>8</td>
<td>35</td>
</tr>
<tr>
<td>4/17/2009</td>
<td>Dog C</td>
<td>31</td>
<td>6</td>
<td>1/8</td>
<td>5/23</td>
<td>1</td>
<td>19</td>
</tr>
<tr>
<td>4/20/2009</td>
<td>Dog D</td>
<td>10</td>
<td>3</td>
<td>1/5</td>
<td>2/5</td>
<td>1</td>
<td>30</td>
</tr>
</tbody>
</table>

*PCR = polymerase chain reaction.*

---
that there was no cross-contamination of reagents. All samples were tested as two replicates, and melting curves were analyzed for each amplicon by using an iCycler (Bio-Rad). For all PCR-positive ticks a 70–602 nucleotide fragment of *ompA* was amplified by semi-nested PCR, purified, and sequenced by using the BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA) according to the manufacturer’s recommendations on an ABI 3130xl genetic analyzer. Sequencing reads were assembled by using Sequencher 4.8 (Gene Codes, Ann Arbor, MI). Homologous sequences were detected by using the National Center for Biotechnology Information (Bethesda, MD) Basic Local Alignment Sequence Tool search engine.

RESULTS

Description of canine cases and the study site. Dog A, a German shepherd, was brought to a local veterinarian on July 22, 2007, August 26, 2007, and April 13, 2009, with episodes of anorexia, lethargy, leukopenia, increased levels of liver enzymes, and heavy *Rh. sanguineus* infestation. Seropositivity to SFGR was established by using *R. rickettsii* antigen and a commercial IFA (titer = 1:128) after the second episode of illness. Oral doxycycline was prescribed and resulted in complete recovery. Doxycycline administered after the third episode resulted in minimal improvement and the dog was humanely killed because of its continued poor health. Dog B, a Doberman pinscher mixed breed, had similar tick infestation and mild illness, accompanied by fever and IgG titers to *R. rickettsii* antigen (titer = 1:512) in March 2008.

The dog owner used a pyrethrin-shampoo bath and topical fipronil for animal treatment and amitraz-impregnated collars for all dogs, and pyrethroid-based spray for environmental tick control in August 2007, and reported successful results until efforts ceased in 2008. Tick numbers then began to increase considerably again on the dogs by late spring of 2009.

Tick testing results. All ticks collected from dogs and from the property were morphologically identified as *Rh. sanguineus*; their 12S mitochondrial rDNA (*HM014444*) had the highest nucleotide sequence identity to the homologous gene of *Rh. sanguineus* from Oklahoma (AF081829) and the Mediterranean region (AF150020 and AF150018). Thirty-two of 50 questing ticks (61 of 267) (Table 1). The *ompA* fragment (70–602 nucleotides) was amplified by semi-nested PCR and sequenced from four PCR-positive tick DNAs. Only one *ompA* genetic type was identified (*HM014444*); amplicons sequenced were identical to each other and had 99% and 100% sequence similarity, respectively, to the homologous fragments of *R. massiliae* ATZT80 and Bar29. The rest of the 50 questing tick samples tested had relatively low copy numbers of the rickettsial DNA (cycle threshold > 36.9), which precluded amplification of the larger *ompA* fragment required for sequence identification of the SFGR. Twelve of 15 *Rh. sanguineus* collected from dog B in late March 2008 were PCR positive for SFGR DNA. Nucleotide sequence of the five amplicons analyzed had 100% sequence identity to the homologous *ompA* fragment of *R. massiliae* Bar29.

After interruption in acaricide applications, tick infestation of all dogs was resurgent in 2009. Five separate collections of 10–155 ticks were made from the dogs (mean = 53.4 ticks/collection, median = 31 ticks/collection, n = 267). SFGR DNA was detected in 4 of 5 tick collections (61 of 267) (Table 1). The PCR-positive ticks were found on each of the four dogs with a prevalence ranging from 19% to 35% (mean = 26.75%). Nucleotide sequences of the 70–602 nucleotide fragment of *ompA* amplicons analyzed were all identical to those of *R. massiliae* Bar29.

Serologic and PCR evaluation of dogs. Serum specimens collected from all four dogs demonstrated broad IFA reactivity for IgM and IgG against antigens from each of the 4 SFGR (Table 2). Antibody titers ≥ 1:64 to each of the SFGR antigens were identified in one or more serum samples from each dog evaluated. Dog A had a previous history of illness and coincident increased *R. rickettsii* IgG titers tested by a commercial laboratory in 2007. In 2009, dogs A, C, and D had IgG titers to *R. massiliae* much higher than cross-reactive IgG titers to *R. hippocophali, R. rickettsii*, and 364D *Rickettsia*.

None of the blood samples obtained from the dogs on the day of their presentation to the veterinarian and necropsy samples of dog A, including brain, lung, heart, liver, spleen, mesenteric lymph node and adrenal gland, were PCR positive for SFGR. No useful etiologic observations were made after hematoxylin eosin staining and immunohistochemical staining for SFGR in postmortem tissues of dog A.

Identification of *rickettsial* agents responsible for seroconversion by Western blotting and serum cross-absorption. Serum samples from all four dogs were tested by Western blotting with four SFGR antigens and showed strong reactivity with high molecular mass proteins ranging from 116 kD to 127 kD (Figure 1A). Samples also contained antibodies reacting with low molecular mass proteins and lipopolysaccharide

### Table 2

Detection of antibodies to spotted fever group *Rickettsia* antigens in canine sera, California*

<table>
<thead>
<tr>
<th>Dog</th>
<th>Date of serum collection</th>
<th><em>R. massiliae</em> ATZT80</th>
<th><em>R. hippocophali</em> 3-7/-6</th>
<th><em>Rickettsia</em> 364D</th>
<th><em>R. rickettsii</em> Bitterroot</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>8/26/2007</td>
<td>256 (128)</td>
<td>256 (128)</td>
<td>128 (256)</td>
<td>1,024 (512)</td>
</tr>
<tr>
<td></td>
<td>8/28/2007</td>
<td>128 (128)</td>
<td>128 (256)</td>
<td>128 (512)</td>
<td>256 (256)</td>
</tr>
<tr>
<td></td>
<td>4/13/2009</td>
<td>1,024 (&lt; 64)</td>
<td>256 (128)</td>
<td>128 (256)</td>
<td>128 (128)</td>
</tr>
<tr>
<td></td>
<td>4/21/2009</td>
<td>128 (&lt; 64)</td>
<td>&lt; 64 (&lt; 64)</td>
<td>&lt; 64 (128)</td>
<td>&lt; 64 (&lt; 64)</td>
</tr>
<tr>
<td>B</td>
<td>3/24/2008</td>
<td>1,024 (512)</td>
<td>1,024 (2,048)</td>
<td>1,024 (&gt; 2,048)</td>
<td>≥ 2,048 (256)</td>
</tr>
<tr>
<td></td>
<td>5/15/2008</td>
<td>512 (126)</td>
<td>128 (2,048)</td>
<td>512 (512)</td>
<td>1,054 (256)</td>
</tr>
<tr>
<td></td>
<td>4/20/2009</td>
<td>1,024 (128)</td>
<td>&gt; 2,048 (64)</td>
<td>&gt; 2,048 (512)</td>
<td>&gt; 2,048 (64)</td>
</tr>
<tr>
<td>C</td>
<td>4/17/2009</td>
<td>&gt; 2,048 (128)</td>
<td>1,024 (256)</td>
<td>128 (128)</td>
<td>512 (128)</td>
</tr>
<tr>
<td></td>
<td>4/20/2009</td>
<td>&gt; 2,048 (256)</td>
<td>1,024 (512)</td>
<td>256 (256)</td>
<td>256 (128)</td>
</tr>
</tbody>
</table>

*IFN = indirect immunofluorescent antibody.
antigens. However, their detection and visualization were more variable and dependent on the serum working dilution tested. To evaluate the nature of the rickettsial agent responsible for seroconversion, serum absorption with each of four SFGR was performed and each of the depleted sera was tested side-by-side with diluent only–treated homologous serum samples at the same working dilution. Similar absorption results were obtained with serum from each of the four dogs, but are shown only for dog B serum. When absorption was performed with R. massiliae antigen (Figure 1B), it resulted in removal and absence of binding of homologous and heterologous SFGR antibodies from serum samples treated and negative results by Western blotting (Figure 1A). In contrast, when absorption was performed with R. rhipicephali (Figure 1C), 364D Rickettsia (Figure 1D), or R. rickettsii (Figure 1E) antigens, only cross-reactive antibodies to homologous antigens were removed, and reactivity of antibodies to R. massiliae was still detectable.

**DISCUSSION**

To our knowledge, this is the first report of R. massiliae in Rh. sanguineus from California. Our findings expand the known geographic range in North America for R. massiliae, which now includes southern California in addition to a reported focus in Arizona.5 Numerous ticks containing R. massiliae were present on this property during 2008–2009. Canine infection with R. conorii (the etiologic agent of Mediterranean spotted fever) shows clinical symptoms and serum and hematologic abnormalities similar to those of Rocky Mountain spotted fever.34 In both infections, rickettsiemia detectable between days 2 and 12 after inoculation develops in acutely ill dogs. This illness is followed by complete clearance and development of anti-rickettsial IgG; its persistence and titers depend on the number of inoculated rickettsiae.35,36 In contrast, dogs infected with R. montanensis, a SFGR of unknown pathogenicity, remain asymptomatic. However, such exposure is usually sufficient to elicit protective immune response to subsequent inoculation with R. rickettsii.37 Antibody responses in dogs infected with R. rickettsii show a similar pattern of reactivity to R. rickettsii, R. montanensis, R. rhipicephali, and R. bellii. However, treatment with tetracycline causes significant delays in serologic responses of infected dogs to heterologous rickettsial species.37

Two of the four dogs had an illness compatible with mild-to-moderate canine rickettsioses caused by R. rickettsii and R. conorii.34,38,39 Although the two other dogs were never reported to be ill, their serologic evaluation confirmed strong seropositivity to SFGR. The repeated consistent detection of R. massiliae in engorged and questing Rh. sanguineus and serum cross-absorption Western blotting results implicate R. massiliae as the likely etiologic agent responsible for SFGR seropositivity detected in all four dogs. Because only whole blood samples from immune dogs were collected and tested, it is not surprising that PCR detection of rickettsial DNA was not observed. Therefore, subsequent episodes of febrile illness in dog A were probably not caused by repeated and persistent exposure to R. massiliae-infected ticks. Although canine susceptibility to R. massiliae has not been established experimentally or proven clinically, this human pathogen may also cause rickettsial infection in dogs. Furthermore, immune response to R. massiliae will probably prevent infection of dogs with other SFGR.

Natural maintenance of SFGR depends in part on the efficiency of transovarial and transstadial transmission in their tick vectors. However, this vector–agent interaction appears to vary significantly among different rickettsial species and ticks. Our observations demonstrated inefficient and damaging vertical transmission of R. rickettsii in Rh. sanguineus from eastern Arizona.40 In contrast, R. massiliae Mt1 shows efficient transovarial and transstadial transmission in Rh. turanicus, excretion of R. massiliae in saliva and feces of infected
ticks, and transmission through co-feeding to *Rh. sanguineus*. High rates of *R. massiliae* infections were demonstrated in *Rh. sanguineus* collected from dogs in the current study (19–80% prevalence in different collections), in questing Arizona ticks from one household used for isolation of *R. massiliae* AZT80 (25% of 20). Because infection with the agent was not detected in any of 62 and 164 (Eremeeva ME, unpublished data) *Rh. sanguineus* from two other sites in California, it appears that high prevalence rates of *R. massiliae* infections in ticks may arise either from clonal expansion from a single infected female tick or by efficient co-feeding transmission of this agent between ticks in a restricted focus.

Dogs evaluated during this study had high titers of IgG antibody reactive with *R. massiliae*. Similarly, 80% of 152 dogs infested with *R. massiliae*-infected *Rh. sanguineus* in Buenos Aires had antibodies reactive with *R. conorii*. However, a high percentage of ticks removed from seroconverted dogs were PCR positive in both studies, which suggested that antibodies against SFGR in the dogs did not affect significantly either transovarial and transtadial transmission or co-feeding acquisition of *R. massiliae*. How general this finding may be is or which route is impacted more severely by the presence of antibodies in dogs is being evaluated in controlled laboratory studies.

*Rhipicephalus sanguineus* is found throughout the United States. Although it is commonly stated that this tick does not bite humans in this country, there are multiple reports of human exposures to *Rh. sanguineus*. Such human encounters may become more frequent when severe infestations occur. High temperatures are thought to increase the risk of humans being bitten. In temperate climates, *Rh. sanguineus* may establish persistent infestations in the environment and also can penetrate inside houses.

Common steps for prevention of most Ixodid tick exposures, which include avoiding tick-infested areas and wearing protective clothing, are not sufficient for addressing nidicolous *Rh. sanguineus* infestations. Such infestations may also be expensive to eliminate and may recur (as in this report) after partial attempts at eradication. Routine canine inspections and use of shampoos and tick treatments are effective approaches, but persisting infestations require environmental control measures, including the services of professional exterminators. Households with fewer resources may be less able to control such infestations. Homeless persons surrounded by dogs are especially vulnerable to bites from *Rh. sanguineus*.

Physicians and veterinarians are encouraged to maintain skills on basic tick identification, to differentiate *Rh. sanguineus* ticks from other Ixodid ticks, and to counsel patients and dog owners on tick control. Physicians in California and elsewhere should consider *R. massiliae* as a potential cause of illness in their patients, especially in those exposed to dogs and *Rh. sanguineus*.

Received June 22, 2010. Accepted for publication November 1, 2010.

Acknowledgments: We thank Gail Van Gordon and Robyn Spano for facilitating this collaboration and for help with specimen storage, Karen Ehnert and Alexandra Swanson for reviewing the manuscript, Sarah Janis and Christopher Tsai for assistance with collection of specimens, Shari Lydy for membrane protein solubilization protocol, Christopher D. Paddock for performing immunohistochemical testing, and Peggy Barr and Linda Kidd for helping set up local surveillance for spotted fever group rickettsiae in dogs. We also thank the owner of the dogs for interest in this study and permission to perform testing.

Disclaimer: The findings and conclusions are those of the authors and do not necessarily reflect the views of the U.S. Department of Health and Human Services.

Authors’ addresses: Emily Beeler, Veterinary Public Health and Rabies Control Program, Los Angeles County Department of Public Health, Los Angeles, CA, E-mail: ebeeler@ph.lacounty.gov. Kyle F. Abramowicz, Maria L. Zambrano, Michele M. Sturgeon, Gregory A. Dasch, and Marina E. Eremeeva, Rickettsial Zoonoses Branch, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, E-mails: kabramowicz@cdc.gov, mzambrano@cdc.gov, msturgeon@cdc.gov, gdasch@cdc.gov, and meremeeva@cdc.gov. Nada Khalaf, VCA McClave Animal Hospital, Reseda, CA, E-mail: nada.khalaf@vca-hospitals.com. Renjie Hu, Vector-Borne Disease Section, Center for Infectious Diseases, California Department of Public Health, Ontario, CA, E-mail: renjie.hut@cdph.ca.gov.

REFERENCES


